Abstract
Objective
Warfarin responsiveness is characterized by marked interindividual variability. A major portion of this variability is attributed to CYP2C9 and VKORC1 polymorphisms, but almost 50% is still unaccounted for. This paper reports the first prospective study on the association between factor VII R353Q polymorphism and warfarin responsiveness during induction.
Methods
Genotyping for factor VII R353Q and 323D/I polymorphisms was performed in a cohort consisting of 374 patients (198 CYP2C9*1/*1) treated with warfarin who were prospectively followed from warfarin initiation.
Results
Compared with *1/*1-R/R and *1/*1-R/Q genotype carriers, *1/*1-Q/Q homozygotes achieved higher International Normalized Ratio (INR) values while consuming lower warfarin doses. The greater sensitivity was illustrated by 82.1% higher Warfarin Sensitivity Index During Induction (WSIDI) (0.14±0.11 vs. 0.08±0.50 mg-1 Mann–Whitney, P = 0.043). Multiple regression analysis consisting of both genetic and nongenetic factors explained 26% of WSIDI variability, with R353Q genetic polymorphism having a modest yet significant effect and accounting for 1.7% of the overall variability. Moreover, the incidence of overanticoagulation (i.e., INR > 4) was 6.94-fold higher among *1/*1-Q/Q vs. *1/*1-R/R&R/Q carriers during warfarin induction (Pearson chi-square, P = 0.005). These findings were not accounted for by a chance difference in the distribution of VKORC1 genotypes. Analysis of these parameters among the entire cohort, including CYP2C9*2 and CYP2C9*3 variant allele carriers, did not reach statistical significance. Warfarin responsiveness during induction was unrelated to factor VII 323D/I genetic polymorphism.
Conclusions
The response to warfarin during induction is influenced by factor VII R353Q polymorphism. The prospective use of this polymorphism, along with CYP2C9 and VKORC1, may enhance the accuracy of warfarin loading. However, the impact of R353Q polymorphism on overall warfarin response is subtle, and it is therefore unlikely that its use would be of clinical importance.
References
Lamb E (2007) Top 200 prescription drugs of 2006. Pharm Times May:34–37
Wallvik J, Själander A, Johansson L, Bjuhr O, Jansson JH (2007) Bleeding complications during warfarin treatment in primary healthcare centers compared with anticoagulation clinics. Scand J Prim Health Care 25(2):123–128
Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115(21):2689–2696
Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH (1996) The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 124(11):970–979
Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348:423–429
Vecsler M, Loebstein R, Almog S, Kurnik D, Goldman B, Halkin H et al (2006) Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 95:205–211
Stafford DW (2005) The vitamin K cycle. J Thromb Haemost 3:1873–1878
Caraco Y, Blotnick S, Muszkat M (2008) CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 83:460–470
Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C, Deych E et al (2007) Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 110(5):1511–1515
Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG et al (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16(2):101–110
Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A et al (2001) Interindividual variability in sensitivity to warfarin - nature or nurture? Clin Pharmacol Ther 70:159–164
Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72(6):702–710
Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and Warfarin dose. N Engl J Med 352:2285–2293
Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S et al (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4):784–792
The International Warfarin Pharmacogenetics Consortium (2009) Estimation of the Warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:753–764
Bertolaa JP, Mazoyerb E, Bergmanna JFO, Drouetb L, Simoneaua G, Mahe I (2003) Early prediction of the sensitivity of warfarin in elderly patients by the fall in factor VIIc and protein C at the induction of treatment. Thromb Res 109:287–291
Green FR, Kelleher C, Wilkes H, Temple A, Meade TW, Humphries SE (1991) A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 11:540–546
Van't Hooft FM, Silveira A, Tornvall P, Iliadou A, Ehrenborg E, Eriksson P et al (1999) Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration. Blood 93:3432–3441
Grimaudo S, Craxi A, Gentile S, Di Paolantonio T, Vaccaro A, Venezia G et al (2005) Prolonged prothrombin time, Factor VII and activated FVII levels in chronic liver disease are partly dependent on Factor VII gene polymorphisms. Dig Liver Dis 37(6):446–450
Mtiraoui N, Aboud N, Bouraoui H, Haizem S, Gris JC, Busson M et al (2005) Reduction in coagulation factor VII plasma levels by R353Q but not the -323P0/10 promoter polymorphism in healthy Tunisians. Am J Hematol 79:11–16
Jeffery S, Poloniecki J, Leatham E, Bevan D, Ireson N, Talbot S et al (2005) A protective contribution of the Q allele of the R353Q polymorphism of the Factor VII gene in individuals with chronic stable angina? Int J Cardiol 100:395–399
Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D et al (2006) Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 79(4):291–302
Lane A, Green F, Humphries S, Ruddock V, Meade T (1995) Effect of factor VII genotype on response to warfarin treatment. Thromb Haemost 73(2):325
Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T et al (2004) Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103:2630–2635
Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C et al (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121:23–34
Ken-Dror G, Drenos F, Humphries SE, Talmud PJ, Hingorani AD, Kivimaki et al (2010) Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men. J Thromb Haemost 8:2394–2403
Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N et al (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5(3):e1000433, Epub 2009 Mar 20
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, American College of Chest Physicians (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):160S–198S
Dell'Acqua G, Iacoviello L, D'Orazio A, Di Bitondo R, Di Castelnuovo A, Donati MB (1997) A polymorphic cluster in the 5' region of the human coagulation factor VII gene: detection, frequency, and linkage disequilibrium. Thromb Res 88(5):445–448
Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F (1999) Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254(3):628–631
Gaunt TR, Rodríguez S, Day IN (2007) Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX'. BMC Bioinformatics 8:428
Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS (2005) Systematic overview of Warfarin and its drug and food interactions. Arch Intern Med 165:1095–1106
Feng D, Tofler GH, Larson MG, O'Donnell CJ, Lipinska I, Schmitz C, Sutherland PA et al (2000) Factor VII gene polymorphism, Factor VII levels, and prevalent cardiovascular disease: the Framingham heart study. Arterioscler Thromb Vasc Biol 20:593–600
Sakata T, Kario K, Matsuo T, Katayama Y, Matsuyama T, Kato H et al (1995) Suppression of plasma-activated factor VII levels by warfarin therapy. Arterioscler Thromb Vasc Biol 15(2):241–246
Weinstock DM, Chang P, Aronson DL, Kessler CM (1998) Comparison of plasma prothrombin and factor VII and urine prothrombin F1 concentrations in patients on long-term warfarin therapy and those in the initial phase. Am J Hematol 57:193–199
Veeger NJ, Piersma-Wichers M, Tijssen JG, Hillege HL, van der Meer J (2005) Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous Thromboembolism. Br J Haematol 128:513–519
Acknowledgments
The study was supported by a grant from the Bi-National US–Israel Science Foundation (YC), a grant from the Israeli Science Foundation (YC) and a grant from the Israeli Ministry of Health (YC). We greatly appreciate the administrative help of Miss Ilanit Linzer.
Authorship
Contribution: LM declared that she participated in planning the study design, in performing genetic analysis, analyzing data, and writing the paper and that she has seen and approved the final version; IBA declared that she participated in recruiting patients for the study, participated in performing the genetic analysis design, and has seen and approved the final version; MM declared that he participated in recruiting patients for the study and has seen and approved the final version; YC declared that he participated in planning the study design, supervising the study, analyzing data, and writing the paper, and that he has seen and approved the final version.
Conflict of interest
The authors declare no competing financial interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mlynarsky, L., Bejarano-Achache, I., Muszkat, M. et al. Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers. Eur J Clin Pharmacol 68, 617–627 (2012). https://doi.org/10.1007/s00228-011-1143-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-011-1143-z